|Last Update: 05/17/13 - 4:00 PM EDT|
|YTD Performance: -25.63%|
|Previous Close: $68.61|
|52 Week Range: $62.34 - $110.79|
|Oustanding Shares: 112,961,747|
|Market Cap: 7,750,305,462|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||13||12||14||13|
|Growth Rate (Year over Year)||14.24%||20.83%||13.38%||20.63%|
EW earnings estimates were increased to reflect additional buybacks, said UBS.
Shares of EW now seen reaching $73, according to Credit Suisse. Estimates also reduced, given higher expected TAVI costs. Neutral rating.
EW was downgraded from Buy to Neutral, Lazard Capital Markets said. Company lacks visibility and will post lower earnings growth.
EW earnings estimates through 2015 were reduced significantly after the U.S. TAVI miss and guidance cut, said UBS. Price target goes to $64.
Portfolio Mgr. David Peltier analyzes one of the early low-dollar winners of 2013.
Shares of EW now seen reaching $114, Jefferies said. Estimates also raised on Sapian launch back on track. Buy rating.
EW was initiated with a Market Perform rating, JMP Securities said. Company trades at a premium to its peers, but has limited upside earnings potential.
Shares of EW now seen reaching $98, Citigroup said. Estimates also increased on greater US TAVI revenues. Nuetral rating.
Portfolio Mgr. David Peltier analyzes a low-dollar stock on the verge of a potential turnaround.